欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目前心脑血管疾病是导致人类死亡的主要病因,血小板的激活和聚集在其形成过程中起到核心作用。大量临床实践发现,不同个体对抗血小板药物的反应有着较大差异,有的患者甚至出现对这些药物产生抵抗的现象。研究表明,遗传因素是导致抗血小板药物疗效产生个体差异的重要原因之一。该综述概述了国内外对抗血小板药物在遗传药理学方面的最新研究进展。
英文摘要：
Nowadays,cerebrovascular disease is one of the main causes of human death.Activation and aggregation of the platelet play core roles in the development of cerebrovascular diseases.A lot of clinical applications have showed that there are great interindividual differences in the response to antiplatelet drugs,and many patients have developed drug resistances.Pharmacogenetic studies have revealed that genetics is one of the key factors resulting in the interindividual differences of the response to antiplatelet drugs.In this overview,the newest advancement in pharmacogenetics is summarized with respect to the antiplatelet drugs.
同期刊论文项目
同项目期刊论文
LC-MS-MS Quantitative Determination of Ursolic Acid in Human Plasma and Its Application to Pharmacok
Inhibition of organic anion-transporting polypeptide1B1 by quercetin: an in vitro and in vivo assess
LC-MS-MS Quantitative Determination of Brivudine in Human Plasma and Its Application to Pharmacokine
The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacody
期刊信息
位置：